SEC Form 4 · accession 0001140361-17-045842
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Michael Kavanaugh
Officer — CSO, Head Res.&Non-Clin. Dev.
Period of report
Dec 8, 2017
Accepted (ET)
Dec 12, 2017 · 2:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 8, 2017 | M | 5,130 | $1.5749 | A | 19,047 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.5749 | Dec 8, 2017 | M | 5,130 | D | — | Feb 8, 2025 | Common Stock | 5,130 | 240,912 | D |
Explanation of responses
- F1This option vests 25% on January 9, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month.